{"schema_version":"secwatch.filing_event.v1","accession":"0001703057-26-000027","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2026-05-11T20:11:11+00:00","discovered_at":"2026-05-11T20:13:00.402887+00:00","generated_at":"2026-05-11T22:16:45.792366+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AbCellera reports Q1 net loss $43.2M; positive Phase 1 data for ABCL635 supports monthly dosing","bullets":["Net loss of $43.2M ($0.14 loss per share) vs $45.6M loss in Q1 2025; revenue $8.3M up from $4.2M.","Total available liquidity ~$655M ($531M cash + $124M non-dilutive government funding).","ABCL635 Phase 1: favorable tolerability, no liver toxicity; half-life ~24 days supports monthly subcutaneous dosing.","ABCL635 showed sustained dose-dependent suppression of testosterone, a validated NK3R biomarker.","Partner-led programs with downstreams: 40 (down from 44); 14 molecules in clinic unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001703057-26-000027","json":"https://secwatch.observer/filing/0001703057-26-000027.json","markdown":"https://secwatch.observer/filing/0001703057-26-000027.md","text":"https://secwatch.observer/filing/0001703057-26-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000027/0001703057-26-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000027/abcl-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:16:45.792366+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}